Favorable Effects of Pioglitazone and Metformin Compared with Gliclazide on Lipoprotein Subfractions in Overweight Patients with Early Type 2 Diabetes

Diabetes Care

Volumn 27, Issue 1, 2004, Pages 41-46

  Lawrence, James M ^a,c   Reid, Julia ^a   Taylor, Gordon J ^b   Stirling, Chris ^a   Reckless, John P D ^a  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID; PIOGLITAZONE; PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METFORMIN; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 1042268743     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.1.41     Document Type: Article

References (34)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 351:1755-1762, 1998
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
4. Barakat HA, Vadlamudi S, MacLean P, MacDonald K, Pories WJ: Lipoprotein metabolism in non-insulin-dependent diabetes mellitus. J Nutr Biochem 7:586-598, 1996
5. Austin M, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
6. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187-195, 1992
7. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881, 1996
8. Silverman DI, Ginsburg GS, Pasternak RC: High-density lipoprotein subfractions. Am J Med 94:636-645, 1993
9. Tack CJ, Smits P, DeMacker PNM, Stalenhoef AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
10. Hirano T, Yoshino G, Kazumi T: Troglitazone and small low density lipoprotein in type 2 diabetes. Ann Intern Med 129:162-163, 1998
11. Sunayama S, Watanabe Y, Ohmura H, Sawano M, Shimada K, Mokuno H, Daida H, Yamaguchi H: Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 146:187-193, 1999
12. Nozue T, Michishita I, Minagawa F, Genda A: Troglitazone directly increases HDL cholesterol levels (Commentary). Diabetes Care 22:355-356, 1999
13. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12:413-423, 2001
14. Hanefeld M, Göke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 108 (Suppl. 2): 256-266, 2000
15. Einhorn D, Rendell M, Rosenzweig J, Egan J, Mathisen AL, Schneider R, Pioglitazone 027 Study Group: Pioglitazone hydrochloride in combination with metformin in treatment of type 2 diabetes mellitus: a randomised, placebo-controlled study. Clin Ther 22:1395-409, 2000
16. Hokanson JE, Austin MA, Brunzell JD. Measurement and clinical significance of low-density lipoprotein subclasses. In Handbook of Lipoprotein Testing. Rifai N, Warnick GR, Dominiczak MH, Eds. Washington, DC, AACC Press, 1997, p. 267-282
17. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA: Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23:1206-1223, 1982
18. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins. Nelson GJ, Ed. New York, Wiley-Interscience, 1972, p. 181-274
19. UK Prospective Diabetes Study Group: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex (UKPDS 27). Diabetes Care 20:1683-1687, 1997
20. Aronoff SL, Rosenblatt S, Braithwaite S, Egan J, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomised placebo-controlled dose-response study. Diabetes Care 23:1605-1611, 2000
21. Rains SGH, Wilson GA, Richmand W, Elkeles RS: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 5:653-658, 1988
22. Chu NV, Caulfield M, Kong APS, Mudaliar SR, Kim DD, Reitz R, Henry RR, Reaven PD: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:542-549, 2002
23. Chapman MJ, Guérin M, Bruckert É: Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches (Review). Eur Heart J 19 (Suppl. A):A24-A30, 1998
24. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ: Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 37:12867-12874, 1998
25. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ: Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 17:2507-2514, 1997
26. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ: Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998
27. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J: Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261-271, 1996
28. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
29. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick H: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825, 1992
30. 3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17:1098-1105, 1997
31. Kobayashi J, Nagashima I, Hikita M, Bujo H, Takahashi K, Otabe M, Morisaki N, Saito Y: Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433-439, 1999
32. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y: The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35-41, 1999
33. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD, Rosiglitazone Study 108 Investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes. Am J Cardiol 90:947-952, 2002.
34. Anurag P, Anuradha CV: Metformin improves lipid metabolism and attenuates lipid peroxidation in high fructose-fed rats. Diabetes Obes Metab 4:36-42, 2002